Q&A: Can in­haled vac­cines mount come­back for one-time leader in Chi­na's Covid race?

SAN FRAN­CIS­CO — In the still-un­fold­ing chron­i­cle of Covid-19 vac­cine his­to­ry, March 16, 2020 might bear an en­try on how the NIH dosed the first vol­un­teer with Mod­er­na’s mR­NA vac­cine. Much less re­mem­bered, though, is the fact that on the same day, a then-11-year-old Chi­nese vac­cine mak­er re­ceived the green­light from reg­u­la­tors in Chi­na to be­gin its own first-in-hu­man tri­al for an ade­n­ovi­ral vec­tor-based shot.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER